http://www.siegfried.ch/ Latest News from www.siegfried.ch en http://www.siegfried.ch/typo3conf/ext/tt_news/ext_icon.gif http://www.siegfried.ch/ 18 16 Latest News from www.siegfried.ch TYPO3 - get.content.right http://blogs.law.harvard.edu/tech/rss Fri, 20 Apr 2012 09:15:00 +0200 http://www.siegfried.ch/news/article/profit-distribution-of-1-swiss-franc-per-share-confirmed/479997e18f680d5a88955715874d563d/ General Meeting of Shareholders of Siegfried Holding AG approves all proposals > download pdf
The General Meeting of Shareholders of Siegfried Holding AG (SIX: SFZN) approved all proposals of the company’s Board of Directors. After two years without a dividend, shareholders will therefore receive a payout of CHF 1.00 per authorized registered share from the capital contribution reserves. Some 300 shareholders representing 57% of the share capital participated in Siegfried Holding AG’s 109th General Meeting of Shareholders held in the Zofingen City Hall today. The shareholders took the following decisions:

• Approval of the 2011 annual report, 2011 annual financial statement and the 2011 consolidated financial statement
• Payout of about CHF 3.7 million from capital contribution
• Discharge granted to members of the Board of Directors and the Executive Committee
• Reelection of the Board of Directors for a one-year period of service: Gilbert Achermann, Reto Garzetti, Dr. Beat In-Albon, Dr. Felix K. Meyer and Dr. Thomas Villiger
• Confirmation of PricewaterhouseCoopers AG as auditors for a further one-year term of office

The Board of Directors for the 2012 financial year is constituted as following:

• Chairman of the Board of Directors: Gilbert Achermann
• Vice-Chairman of the Board of Directors: Dr. Andreas Casutt
• Chairman of the Audit Committee: Dr. Andreas Casutt
• Chairman of the Strategy Committee: Dr. Beat In-Albon
• Chairman of the HR Committee: Dr. Thomas Villiger

]]> Fri, 20 Apr 2012 09:10:00 +0200 http://www.siegfried.ch/news/article/continued-upward-trend/017ce85e9890498be9d433559796b643/ The Siegfried Group reported gratifying results for the 2011 financial year despite a demanding... > download pdf

• In 2011 Siegfried achieved a gratifying result in a demanding market environment
• The company succeeded to distinctly increase sales and profitability and to achieve a net profit.
• After two years without paying a dividend, the Board of Directors proposes paying of CHF 1.00 per share.
• Without the strong appreciation of the Swiss franc compared to the Euro and the US dollar, Siegfried’s key performance indicators would have been clearly more positive
• In 2011, Siegfried further strengthened its competitive situation and established itself as a flexible, reliable and competent supplier and outsourcing partner of the Life Science industry
• The company aims to further strengthen its competitive situation and make significant progress in terms of cost structure and earnings power by means of three strategic priorities: backward integration in Asia, entry into sterile filling, and enhancement of the technological basis
• Siegfried expects continued improvement in 2012 of its key operating performance indicators 

The Siegfried Group reported gratifying results for the 2011 financial year despite a demanding market environment. The company’s sales grew also in terms of Swiss francs and profitability increased distinctly. Moreover, Siegfried returned to a net profit. Based on these results and on the sound business development, the Board of Directors proposes to pay out CHF 1.00 per share following two years without dividend payout.  The Siegfried Group generated sales of CHF 328.1 million for the 2011 financial year, representing a growth of 4.4% in terms of Swiss francs. In local currencies, sales grew by 15.6%. Earnings before interest, taxes, depreciation and amortization (EBITDA) amounted to CHF 41.0 million (+ 11.9%), corresponding to an EBITDA margin of 12.5%.  Decisive growth (+ 116%) was achieved in earnings before interest and taxes (EBIT), which amounted to CHF 11.6 million, or 3.5% of sales. Adjusted for currencies, Siegfried reports an EBIT margin of 4.6%. The resulting net profit of CHF 9.6 million corresponds to earnings per share of CHF 2.61. Without the strong appreciation of the Swiss franc, Siegfried’s key indicators would have been clearly more positive. Net working capital remained at a low CHF 122.2 million. The 14.5% rate of return on capital employed (ROCE) shows that a good performance was achieved with committed resources. At year-end Siegfried reported cash holdings of CHF 52.6 million.  In view of the good results and the sound financial situation, the Board of Directors proposes paying of CHF 1.00 per registered share from the capital contribution reserve. Rudolf Hanko, CEO, said: “In 2011, Siegfried made clear operational progress and achieved a gratifying result. We have returned to profitability, improved our market position and increased efficiency at high capacity utilization. Moreover, we are working on our strategic targets at full speed”.  All production facilities operating at high capacity utilization Siegfried achieved growth in exclusive synthesis and in the production of portfolio active pharmaceutical ingredients (controlled substances). Sales in both fields each grew by about 10% in Swiss francs or approximately 20% in local currencies. Siegfried reported a sales decline of 18% (or 11% in local currencies) in the field of finished drugs as some of the main pillars of sales in this field are reaching the end of their product life cycle, and their sales contribution has not yet been fully substituted by new products. However, renewal of the portfolio is running on schedule.  The gratifying sales development is reflected by high capacity utilization at all Siegfried production facilities. In Zofingen, large segments of production switched to a 7-day/24-hour cycle, and in Pennsville, USA, the production plants were in operation six days a week on average. In Malta, the workforce was increased considerably in view of the introduction of an important product in 2012. Thanks to across-the-board cost discipline, the rising sales had a correspondingly positive effect on the financial results.   Continued improvement of earnings situation expected  Within the parameters of strategy implementation, Siegfried will continue to focus on three areas to secure its competitive position over the long term: backward integration in Asia, entry into sterile filling, and enhancement of the technological basis.  Despite demands made by the market and a continuing pressure on prices, Siegfried expects sales in 2012 in local currencies to develop at a stable rate. Higher capacity utilization and increased efficiency will further improve operating results.  Changes in the Board of Directors  Thomas Staehelin, Vice-Chairman of Siegfried’s Board of Directors, will resign from the Board on the occasion of the annual general meeting scheduled for April 20, 2012. After 21 years of service, he will not stand for reelection. All other Board members will stand for reelection for a further one-year period of office. The Board of Directors will propose no further nominations. For further information: Financial Analysts:
Michael Hüsler, CFO
michael.huesler@siegfried.ch
Tel. +41 (0)62 746 11 35 Media:
Peter A. Gehler, Head Corporate Center
peter.gehler@siegfried.ch
Tel. +41 (0)62 746 11 44
Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
www.siegfried.ch
About Siegfried The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Malta and the USA. At the end of 2011, Siegfried employed approximately 700 employees and reported annual sales of CHF 328 million. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN). Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms. ]]> Mon, 05 Mar 2012 20:44:00 +0100 http://www.siegfried.ch/about-siegfried/events/ 5th Siegfried Symposium 2012, October 5th at the METROPOL in Zurich Tue, 07 Feb 2012 15:27:00 +0100 http://www.siegfried.ch/news/article/siegfried-was-presented-with-novartis-global-supplier-award-for-2011/ecb42d3e2c20cab7d3bedfcb8448acb6/ Novartis, the Swiss pharmaceutical company, bestowed the 2011 “Global Supplier Award” on Siegfried....
> Download PDF

Under the motto “Value creation through innovation”, Siegfried has made a decisive contribution toward the market success of a drug currently on sale in the USA. The process development for the active pharmaceutical ingredient (API) was carried out in Siegfried’s Pennsville (USA) plant where it is also being produced. The project is exemplary for Siegfried’s cooperation with customers in the pharmaceutical industry. The development of a demanding API takes several years and requires careful coordination among various areas of expertise in the field of process chemistry. The areas of expertise include analytical, scale-up to industrial quantities, and production with a high awareness for quality.

Marianne Späne, Siegfried’s Head of Business Development & Sales: “The aim of a successful supplier-customer model is to grow a business idea into a cooperation based on partnership that will lead to a successful strategic alliance. For us, the Novartis Supplier Award is proof that Siegfried is on the right track and is one of the world’s leading suppliers.”



For further information:
Peter Gehler, Head Corporate Center
peter.gehler@siegfried.ch
Tel. +41 (0)62 746 11 48
Mobile +41 (079) 416 41 16
Fax +41 (0)62 746 11 03

Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax  +41 (0)62 746 11 03


About Siegfried
Active in Life Science markets, the Siegfried Group is a global manufacturer of pharmaceutical products with production facilities located in Switzerland, Malta and the USA. At the end of 2010, Siegfried employed approximately 700 employees and achieved annual sales of CHF 314 million. Siegfried Holding AG is listed on the Swiss Exchange in Zurich (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and standard products, and provides development and production services for drugs in finished dosage forms.


]]> Wed, 07 Dec 2011 13:02:00 +0100 http://www.siegfried.ch/news/article/sales-growth-continues-strategy-implementation-on-track/61aca35f3c60164233aac271cdcecbd4/ The Siegfried Group (SIX: SFZN) achieved solid results and returned to profitability during the... > Press Release Net sales increased by 28.3% over 2010, to CHF 173.8 million and earnings before interest, taxes, depreciation and amortization (EBITDA) were CHF 18.9 million (2010: CHF 17.2 million), or a 10.9% margin. Net profit reached CHF 2.4 million. In terms of operations and strategy, the company is on track and the necessary funds for implementation of the strategy are available. The outlook for 2011 remains positive.
Despite the demanding economic environment that characterized the first six months of 2011, the Siegfried Group returned to profitability and continued to make progress with strategic and operational priorities. The company increased net sales by 28.3%, to CHF 173.8 million over 2010 (in local currencies: +42.4%). Earnings before interest, taxes, depreciation and amortization (EBITDA) grew by 10.2% to CHF 18.9 million (previous year: CHF 17.2 million), or a 10.9% margin. As Siegfried responded early to the unpredictable developments in the currency markets by implementing corresponding measures, the negative effects of a strong Swiss franc on operating profits were kept within a tolerable range. The Siegfried Group achieved an operating cash flow of CHF 18.2 million (2010: CHF 11.5 million).
Dr. Rudolf Hanko, Siegfried CEO: "Siegfried is running smoothly. Our sales growth, achieved in difficult economic environment, underlines our competitive strength. Combined with our strong balance sheet, we are in an excellent position to take the necessary steps to create a foundation for sustainable growth and increased profitability."
Exclusive Synthesis drives growth
The Siegfried Group reported strong growth for the first half of 2011 thanks to significant increase in API sales. Exclusive Synthesis contributed the lion's share, with over 50% in growth, contributing over 60% of total revenues. Controlled substances, including APIs for analgesics and opiates, also continue to grow, especially in the European market. These products contributed about 20% of sales during the first half of 2011.
Siegfried is striving to develop new Drug Products. Due to the considerable risks involved, these efforts are generally carried out with partners that contribute additional technology skills or enable a market entry in specific countries. The first market launches are expected by the end of this year. In addition, Siegfried has increased collaboration with research-based customers. However, these development contracts are complex and long-term.
Outlook
Siegfried sees significant sales growth (in local currencies) for 2011. The EBITDA margin should be similar to the first half of the year; the company expects a net profit for the year.
Dr. Rudolf Hanko: We want to use the momentum of our progress in operations to achieve a sustainable improvement in our competitive position. Siegfried continues to focus on improving our market position and the targeted promotion of our USP the combined offer of APIs and drug products. As a strong partner for the life sciences industry, we strive to strengthen our position even further.
For further information:

Michael Hüsler, CFO
michael.huesler@siegfried.ch
Phone +41 (0)62 746 11 35
Fax +41 (0)62 746 11 03

Siegfried Holding AG
Untere Brühlstrasse 4
CH-4800 Zofingen
Tel. +41 (0)62 746 11 11
Fax  +41 (0)62 746 11 03

www.siegfried.ch

]]> Thu, 25 Aug 2011 06:41:00 +0200 http://www.siegfried.ch/news/article/change-in-siegfried-s-board/01fbe9108a602ae62e79c2db5ae4dada/ The shareholders meeting of Siegfried Holding AG approved all proposals put forward by the Board of... > Press Release Shareholders elect four new members onto the Board Change in Siegfried's Board The shareholders meeting of Siegfried Holding AG approved all proposals put forward by the Board of Directors. Gilbert Achermann, Binningen, Reto Garzetti, Zurich, Dr. Beat In- Albon, Oberwil BL and Dr. Thomas Villiger, Muttenz were newly elected onto Siegfried's Board. Gilbert Achermann will succeed Dr. Markus Altwegg as Chairman. The term of office for Board members was reduced from three years to one year. Rudolf Hanko, Siegfried's CEO, confirmed the outlook for the 2011 financial year. As announced earlier, he expects both sales and profitability to rise. Moreover, he anticipates the implementation of significant strategic projects during the current year. ]]> Tue, 24 May 2011 10:48:00 +0200 http://www.siegfried.ch/news/article/siegfried-group-announces-management-changes/4eaf0bab07efc2d338be277bbbe3b6e5/ Siegfried Holding AG (SIX: SFZN), based in Zofingen, Switzerland, announces the appointment of two... > Press Release  Siegfried Holding AG (SIX: SFZN), based in Zofingen, Switzerland, announces the appointment of two new members to its Executive Committee. With effect from 1 June 2011, Walter Kittl, Senior Vice President and General Manager of Siegfried (USA) Inc., will take on responsibility as Head Technical Operations and join the Executive Committee in Zofingen. He will remain responsible for the Pennsville location until such time as his successor has been appointed. Walter Kittl is an Austrian national and holds a Ph.D. in chemistry from the University of Innsbruck. Prior to his commitment for Siegfried, he was employed by DSM Chemie Linz and Hoffmann-La Roche in Basel, where he was head of chemical production. In his new function, Walter Kittl will succeed Hubert Stückler, who will retire from this position at his own request. For a limited period of time, Hubert Stückler will continue to work for Siegfried on the implementation of the "Transform" strategy. Arnoud Michael Middel was appointed Head Human Resources and a member of the Executive Committee with effect from 1 September 2011. He will succeed Hanspeter Brun, who will retire. Arnoud Middel, a Dutch national, graduated from the University of Basel in biology and biochemistry. He subsequently worked in human resources for several companies, currently Syngenta in Basel, where he holds the position of Head HR Switzerland and Global Headquarter. Rudolf Hanko, Siegfried's CEO: "Walter Kittl and Arnoud Michael Middel are very well qualified for their new positions, and I am pleased they will join our Executive Committee. I would like to thank Hanspeter Brun and Hubert Stückler, who joined our company in 1989 and 2004 respectively, for the many years of dedicated service and the valuable contribution to the successful development of our company."]]> Sat, 21 May 2011 17:37:00 +0200 http://www.siegfried.ch/news/article/siegfried-mandatory-convertible-bond-completely-converted/7ae89dcabcd96a0f2c4046841e0a6e18/ Siegfried issued a 5% mandatory convertible bond due 2011 on April 26, 2010. > PDf Siegfried issued a 5% mandatory convertible bond due 2011 on April 26, 2010. All outstanding notes of the original issue amount of 80 million Swiss Francs were converted by the maturity date, May 5, 2011. Consequently, Siegfried Holding AG's issued share capital now amounts to 3,800,000 registered shares at a par value of two Swiss Francs.]]> Fri, 06 May 2011 06:16:00 +0200 http://www.siegfried.ch/news/article/siegfried-reports-clearly-higher-operating-results-for-2010/c4dbb6ed3701197664074f6b824b8ba3/ Siegfried Holding AG (SIX: SFZN) reports sales of CHF 314.4 million for the 2010 financial year,... > Press Release Siegfried Holding AG (SIX: SFZN) reports sales of CHF 314.4 million for the 2010 financial year, corresponding to a growth of 11.1% over the previous year, or of 14.2% in local currencies. Earnings before interest, taxes, depreciation and amortization (EBITDA) rose by 11.5% to CHF 36.7 million (2009: CHF 32.9 million), representing an 11.7% EBITDA margin. EBIT amounted to CHF 5.4 million, following an operating loss of CHF 14.3 million the previous year. Net loss is reported at CHF 4.2 million. When excluding special financial charges of CHF 5.2 million, profit is reported at CHF 1.0 million. While sales in Siegfried's active pharmaceutical ingredients (API) business grew by 14.1% to CHF 252.2 million, sales of CHF 62.2 million in formulated drug products remained at the previous year?s level. Distinctive strengthening of balance sheet In the year under review, net working capital decreased by a further CHF 23 million representing a positive impact on cashflow. Operating cashflow in general developed encouragingly and reached CHF 58 million. At December 31, 2010, Siegfried held net cash amounting to about CHF 40 million. Based on the net cash position and the high equity ratio of 81%, planned acquisitions within the parameters of the strategy can be financed at any time. Strategy implementation on target Siegfried implemented significant steps of its strategy in 2010. In March, Siegfried?s organization was converted from a divisional to a functional structure. At the beginning of May, the Siegfried Group successfully placed CHF 80 million mandatory convertible notes (MCN), which were fully subscribed by Siegfried's shareholders. At the end of September, Siegfried divested its PulmoJet inhalation project as planned to sanofi-aventis and, following market introduction, Siegfried will benefit from royalties. Several measures were implemented in connection with the strategic goal of securing and expanding Siegfried's presence in the USA, such as realigning and strengthening the marketing and sales organization. Capacity utilization of the US plant clearly grew in 2010. Good pipeline On December 31, 2010, Siegfried's development pipeline comprised 31 projects for active ingredients and intermediate products as well as 9 projects for development services connected with formulated drug products, including 3 projects embracing both active pharmaceutical ingredients and galenic formulations. Therefore, combined with a gratifying order backlog for 2011, a basis has been created for continually growing capacity utilization over the coming years. Annual general meeting of shareholders As announced earlier, Dr. Markus Altwegg will retire as Siegfried's chairman due to his age following nine years of service on the Siegfried Board of Directors. The Board appointed Gilbert Achermann as his successor. Gilbert Achermann also serves as chairman of the Straumann Group's Board of Directors. Furthermore, the Board of Directors proposes to the general meeting of shareholders the appointment of Reto Garzetti, Dr. Beat In-Albon and Dr. Thomas Villiger. Susy Brüschweiler and Prof. Dr. Felix Gutzwiller will no longer stand for re-election. Siegfried will disburse 5% interest on the mandatory convertible notes to be paid out in May 2011. The Board of Directors proposes to the annual general meeting of shareholders to waive payment of a dividend again.]]> Thu, 10 Mar 2011 06:00:00 +0100 http://www.siegfried.ch/news/article/change-of-the-guard-at-siegfried/e34545ae9e81b6e7c04fd62a0edd6a99/ Siegfried announces the retirement of its Chairman, Markus Altwegg, due to age with effect from the... > PDF Markus Altwegg (1941) joined the Board of Siegfried Holding AG in 2002 and - following his withdrawal from the Roche Executive Committee was appointed Chairman in 2003. He will not be available for re-election at the next annual meeting of shareholders due to age. In addition, Susy Brüschweiler (1947), Chairwoman of SV-Stiftung, and Prof. Felix Gutzwiller (1948) will not stand for re-election. Both joined the Board in 1999. The following candidates stand to join the Board of Siegfried Holding AG:

• Gilbert Achermann (1964) is designated as Chairman of Siegfried Holding AG in addition to his activities at Straumann.
• Reto A. Garzetti (1960) is Partner in SE Swiss Equities, a Zurich-based asset management company.
• Beat In-Albon (1952) is Head of SGS Group's Industrial Services Division. 
• Thomas Villiger (1951) is a business consultant and former CEO of Mepha.

The annual general meeting of Siegfried Holding AG is to be held in Zofingen on May 24, 2011. Biographical sketches Dr. Markus Altwegg Markus Altwegg (1941) joined the Board of Siegfried Holding AG in 2002 and was appointed its Chairman in 2003. From 1999 to 2003 he was responsible for the international business of Roche Group's Vitamins and Fine Chemicals Division. Preceding that to that he held various other functions in other departments at Roche, in Switzerland and abroad. He was appointed to Roche's Executive Committee in 1986. He furthermore serves on the Board of Energiedienst Holding AG and private bank Sal. Oppenheim AG. He is also a member of numerous industry associations and scientific and charity associations. He is Chairman of the Foundation for the Kunstmuseum Basel, a committee member of the Foundation for the Basel Museum of Ancient Art, a member of the Board of Unitectra, the Technology Transfer Organization of the Universities of Basel, Bern and Zurich. He holds a Ph.D. in Economics from the University of Basel. Susy Brüschweiler Susy Brüschweiler (1947) joined the Board of Siegfried Holding AG in 1999. Following training as a hospital nurse she continued her studies in economics and business administration at the University of Neuchâtel. In 1986 she was appointed head of the Bois- Cerf Nursing School in Lausanne and in 1990 Director of the Specialist Training College for Nursing in Aarau. In 1995 she was appointed head of the former Verein SV-Service, today SV-Group, a position she held until 2010. Subsequently she was appointed Chairwoman of the SV Foundation. Susy Brüschweiler is also on the Boards of Schweizerische Mobiliar Holding AG, Schweizerische Mobiliar Genossenschaft AG. She serves on the Board of the Swiss Paraplegics Association. Susy Brüschweiler is a Honorary Member of the International Committee of the Red Cross (ICRC). Felix Gutzwiller, Councellor of State Felix Gutzwiller (1948) joined the Board of Siegfried Holding AG in 1999. He was appointed professor of preventive medicine at the University of Zurich in 1988 and Head of that university institute. He served the Swiss Parliament as a Member from 1999 to 2007 and as a Councilor of State since 2007. Felix Gutzwiller graduated from the Universities of Basel, Harvard and Johns Hopkins (USA). In addition to his mandate for Siegfried Holding AG, Felix Gutzwiller serves on the Boards of Bank Clariden Leu AG and Axa Winterthur Switzerland AG as well as on several boards of trustees in the areas of charity, science and public health. Felix Gutzwiller is a colonel in the Swiss Army. Gilbert Achermann Gilbert Achermann (1964) joined the Board of Straumann in 2009 and was appointed Chairman in April 2010. He joined Straumann in 1998 as CFO and was appointed CEO in 2002. He held this function until the annual general meeting of Straumann at the end of May 2010. Preceding his employment by Straumann, Achermann worked for UBS in Zurich, Geneva, New York and Frankfurt in the fields of Corporate Finance and Sales & Trading. Gilbert Achermann also serves on the Board of the International Team for Implantology (ITI), and he is a member of the advisory committee for international cooperation of Canton Basel-Stadt. Gilbert Achermann holds an Executive MBA degree from IMD Lausanne and a degree in business administration from the University for Applied Sciencies of St. Gallen. Reto A. Garzetti Reto A. Garzetti (1960) is a partner of SE Swiss Equities, a Zurich-based asset management company (former Schweizerische Gesellschaft für Aktienhandel und Research AG). Preceding that he worked during 10 years for Berater Zentrum AG. Until 2010 he served on the Board of this company. He graduated from the University of Zurich in business administration (lic. oec. publ.) with the main emphasis on banking and law for trade and securities. Beat In-Albon Beat In-Albon (1952) is a member of the Executive Board of Geneva-based SGS Group and Head of its Industrial Services Division. Preceding that he was employed for 20 years by the Lonza Group where he was Head of the Organic Fine & Performance Chemicals Division and member of the Executive Board. He holds a Ph.D. degree in economics from the University of Fribourg (1983). Dr. Thomas Villiger Thomas Villiger (1951) founded his own management consultancy in 2010. From 1986 to 2010 he was employed by Mepha Group, from 1997 onward he leaded the Mepha Group as a CEO. From 1980 - 1986 he worked in various functions for Sandoz in Basel, partly in Japan. He serves on the boards of Dolder AG and the Sigvaris Holding AG. He holds a Ph.D. degree in chemistry from the Swiss Federal Institute of Technology in Zurich (1979).]]> Wed, 26 Jan 2011 22:50:00 +0100 http://www.siegfried.ch/news/article/newsletter-behind-the-scenes-edition-0111/14f71c488e1b6695af3f4e929d053399/ Newsletter 01/11 Part 1: Corporate News DownloadPart 2: Corporate Know-How Download Newsletter 01/11

• Part 1: Corporate News Download
• Part 2: Corporate Know-How Download

]]> Wed, 19 Jan 2011 14:50:00 +0100 http://www.siegfried.ch/news/article/siegfried-signed-outsourcing-agreement-with-ebm/41864afeff22983335f68cdb32ccf2c7/ On 14 January 2011, the Siegfried Group (SIX: SFZN) signed a cooperation agreement for its plant in... > PDF On 14 January 2011, the Siegfried Group (SIX: SFZN) signed a cooperation agreement for its plant in Zofingen with EBM Industriecontracting AG, a subsidiary of the EBM Group, Münchenstein. In terms of the agreement, which becomes effective retroactively as of 1 January 2011, EBM is responsible for all matters concerning supply and waste disposal at Siegfried?s Zofingen location. EBM paid CHF 11.5 million for the acquisition of the corresponding buildings and equipment, and the company will take on the eight members of staff working in the unit. Siegfried CEO Rudolf Hanko: ?As a result of our cooperation with EBM, Siegfried and its customers will benefit from a professional service at lower cost. The step represents a further contribution toward Siegfried?s continued striving to reach higher competitiveness.?]]> Fri, 14 Jan 2011 17:26:00 +0100 http://www.siegfried.ch/news/article/siegfried-reports-distinct-sales-increase-for-first-3-quarters-of-2010/7b55923318946f8652576c5006eb35b7/ The Siegfried Group (SIX: SFZN) reports sales of CHF 218.5 million for the first 9 months of the... > PDF The Siegfried Group (SIX: SFZN) reports sales of CHF 218.5 million for the first 9 months of the 2010 financial year, representing an increase of 8.8% in Swiss francs and of 12.1% in local currencies over the comparable period the previous year. Siegfried sold active pharmaceutical ingredients and intermediates amounting to CHF 172.4 million, CHF 17.5 million or 11.3% over the previous year?s result. Sales of ready formulated drugs amounted to CHF 46.1 million, or a growth of 0.4% over the first three quarters of 2009. In the third quarter, sales of active pharmaceutical ingredients and intermediates continued to develop favorably, exceeding even the previous year?s strong quarterly result. The pleasing sales increase in the current year is attributed mainly to rising sales in the USA. Sales of finished formulated drugs, which today are still delivered largely to generics companies, remained at the previous year?s level despite a heavily contested price war ? especially also in the German market ? and negative currency influences. Outlook Siegfried?s Board of Directors and Executive Committee expect sales growth for the entire 2010 financial year to remain in the high single-digit percentage range. Following divestment of the inhalation business, the operating result (EBITDA) will be disburdened of connected expenses. Siegfried therefore anticipates the EBITDA margin to again rise above 10%.]]> Wed, 27 Oct 2010 17:42:00 +0200 http://www.siegfried.ch/news/article/newsletter-behind-the-scenes-edition-0210/6764ed61936915eb3bf0486c15523ef2/ Part 1: Corporate News Download PDF Part 2: Know-How Download...

Part 1: Corporate News Download PDF      

Part 2: Know-How Download PDF  

]]> Thu, 07 Oct 2010 11:02:00 +0200 http://www.siegfried.ch/news/article/siegfried-sells-pulmojet/992a1679b780b700315c0105fcb9f8b3/ The Siegfried Group (SIX: SFZN) announces the sale of its inhalation project, and therefore its... > PDF ...we have found excellent and experienced developer for PulmoJet?s upcoming clinical tests and a guarantor for its successful market introduction. This solution represents a technical and economic win-win situation for all participants and a good day for the PulmoJet® device?. Strong performance of Siegfried?s development team Siegfried acquired the rights to the PulmoJet® dry powder inhaler in 2007 and within three years continued to develop the device both technically and pharmaceutically. Currently, two pharmaceutical projects for asthma therapy based on the PulmoJet® platform are in the pipeline. A pharmaco-kinetic study was completed in the spring of 2010. Siegfried did not intend to carry out or finance the upcoming broad clinical tests itself. Rob Koremans, the CEO of Zentiva, commenting on today?s news said ?Today?s acquisition provides a real boost to our plans to extend the range of modern high quality affordable medicines to patients. By acquiring the Siegfried Inhaler Franchise we believe we will have a strong competitive position which will allow us to become a leader in affordable respiratory medicines in the future.? Siegfried participates in market success Following market introduction of the two development projects, Siegfried will benefit from related royalty payments. Furthermore, expenses for PulmoJet will cease to apply for Siegfried. All employees to be retained Together with the project, sanofi-aventis will acquire the connected Siegfried subsidiary company in Germany. Consequently, about 50 employees at the Munich (development) and Höchstädt (production) locations will change over to sanofi-aventis.]]> Fri, 01 Oct 2010 06:52:00 +0200 http://www.siegfried.ch/news/article/newsletter-behind-the-scenes-ausgabe-210/a74ef478e4567790e7cd78de34862cf6/ Part 1: Corporate News Download PDF Part 2: Know-How Download PDF

Part 1: Corporate News Download PDF   

Part 2: Know-How Download PDF  

]]> Thu, 30 Sep 2010 13:07:00 +0200 http://www.siegfried.ch/news/article/strong-growth-in-1st-half-of-2010-for-siegfried/5382060d0d1b4c1dfd161a37e19003ca/ With sales of CHF 135.4 million during the first six months of 2010, the Siegfried Group (SIX:... > PDF > Semi-annual report 2010 Siegfried noted again a slight net loss for the first six months of 2010, due to significantly higher financial expenditures caused by the repayment of the bank loans. The company is practically debt-free after issuing CHF 80 million mandatory convertible notes that were successfully placed this past May. Siegfried now has the necessary financial means to implement the new corporate strategy. As previously reported, the inhalation technology business is the object of negotiations with third parties by Siegfried, which are already at an advanced stage. The goal is to find a strong industrial partner; Siegfried will report on the results of negotiations in the near future. ?We?ve reached two important goals by achieving a capital increase and improving our capacity utilization levels,? says Dr. Rudolf Hanko, CEO at Siegfried. ?In addition, compared with our industry, our facilities generate attractive margins and a positive cash flow. This is a promising foundation for the implementation of our strategy and continued progress in our operations.? Significant progress with active pharmaceutical ingredients (API) Significant progress was made with revenues from APIs and intermediates. In a challenging market environment characterized by clients focused on optimizing the supply chain, Siegfried achieved a 14.5% sales increase. In order to replace key products before patent expiry, Siegfried strives to update and rejuvenate its pipeline for APIs and intermediates. We expect the US-company Arena to receive FDA-approval for Lorcaserin soon, an API currently under development in Zofingen. Sales of APIs for analgesics and opiate derivatives, also known as ?multi-client products? continue to grow, which also has a positive affect on capacity utilization at the Pennsville, NJ (USA) facility. Siegfried signed a supply contract for opiate derivatives with a large vendor in US and is currently supporting the registration process. Approval by the US regulatory authorities is expected by 2012. Commercial deliveries will commence at that time. Finished dosage forms also growing Sales of finished formulated drugs, supplied mostly to generics clients, showed some growth. Siegfried noted sales of CHF 31.5 million, 5.8% more than the previous year, which helped alleviate the enormous pressure on generics prices by the public authorities of almost all countries. Faced with the continued price erosion in the generics market, Siegfried expects to maintain positive results in the longer term only through the introduction of new products. Strategy implementation on schedule During the first half year 2010 Siegfried has established the necessary foundation for a quick implementation of our strategy, which centers on marketing combined products (synthesis of APIs and productions of finished dosage forms). This requires an adjustment to the company?s asset base; the corresponding talks are now taking place. In addition, Siegfried plans to add to the operations for API production with an Asian facility. This will help increase the attractiveness of our market offer. Outlook Siegfried expects improved revenues for the whole year 2010 and forecasts a net profit in the core business at the end of the year. ?The reorganization of Siegfried progressed well over the past 12 months. Key is a clear unique selling proposition, our attractive market offer and increased competitive strength,? says Dr. Markus Altwegg, Chairman of the Siegfried Board of Directors. ?We intend to maintain the pace to be able to profit from our new strategy already by next year.?]]> Mon, 30 Aug 2010 18:24:00 +0200 http://www.siegfried.ch/news/article/siegfried-outsources-support-functions/1dfdba91de0bb0c5c5a7ae5158bc5831/ Cooperation with Bilfinger Berger Industrial Services AG and GWE GmbH > PDF Siegfried Holding AG (SIX: SFZN) signed a cooperation agreement with two companies concerning the supply of support functions. In the future, Bilfinger Berger Industrial Services Swiss AG will provide maintenance, part of the engineering and security services and run the Siegfried HAZMAT Training Center. All issues concerning utility supply and waste disposal will be handled by IHKW Industrieheizkraftwerk Zofingen AG, a subsidiary of GWE Gesellschaft für wirtschaftliche Energieversorgung mbH located in Freiburg, Germany.]]> Fri, 30 Jul 2010 17:50:00 +0200 http://www.siegfried.ch/news/article/newsletter-behind-the-scenes-edition-110/c6e18f75c14943b019410e375de41fbd/ Newsletter 1/10 Part 1: Corporate News Download PDFPart 2: Know-how: Siegfried's One Stop... Newsletter 1/10

• Part 1: Corporate News Download  PDF
• Part 2: Know-how: Siegfried's One Stop Shop for partners in the pharmaceutical industry. Download  PDF
  Part 3: Flyer Symposium (23/9/2010) Downlaod PDF

]]> Fri, 23 Jul 2010 16:35:00 +0200 http://www.siegfried.ch/news/article/newsletter-behind-the-scenes-edition-110/52002859eb8ed443e26d41e4421139a0/ Newsletter 1/10 Part 1: Corporate News Download PDFPart 2: Know-how: Siegfried's One Stop... Newsletter 1/10

• Part 1: Corporate News Download  PDF
• Part 2: Know-how: Siegfried's One Stop Shop for partners in the pharmaceutical industry. Download  PDF
  Part 3: Flyer Symposium (23/9/2010) Downlaod PDF

]]> Fri, 23 Jul 2010 16:35:00 +0200